KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Cash at Beginning of Period

Last Annual Value

118.29M

3-Year CAGR

1168%

5-Year CAGR

14%

10-Year CAGR

7%

KT

Kalaris Therapeutics Inc Competitors Analysis of Cash at Beginning of Period

KLRS · NASDAQ
CompanyCash at Beginning of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
118.29M
238.2%-0.7%N/A 
28.23M
-15.5%-17.1%-8.7%
40.49M
-26.7%9.7%N/A
57.39M
6.6%-18.3%N/A
94.43M
38.6%207.9%N/A
32.63M
-44.5%-9.4%N/A
76.98M
2.8%3.9%-10.0%
17.63M
-28.8%-47.3%N/A
71.72M
10.2%19.8%N/A
38.79M
16.2%-24.4%N/A
54.42M
10.4%23.0%32.7%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66